ReviewTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2018
State of the art in factor XIII laboratory assessment.
Review in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation.American journal of hematology · 2026Review
- Factor XIII Deficiency: A Review of Biology, Testing, and Treatment.Clinical hematology international · 2026Review
- High prevalence of factor XIII deficiency and its association with bleeding in extracorporeal membrane oxygenation patients: an observational study from a prospectively compiled biobank.Research and practice in thrombosis and haemostasis · 2025Article
- Review
- Factor XIII: More than just a fibrin stabilizer for the burn patient? A matched-pair analysis.JPRAS open · 2023Article
- A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.Blood transfusion = Trasfusione del sangue · 2023Article
- Identification of a novel mutation in the factor XIII A subunit in a patient with inherited factor XIII deficiency.International journal of hematology · 2023Article
- Automation of a Factor XIII Activity Assay Utilizing a Plasma Blank Measurement.Methods in molecular biology (Clifton, N.J.) · 2023Article
- The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORJournal of thrombosis and thrombolysis · 2022Article
- Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.Arteriosclerosis, thrombosis, and vascular biology · 2022Review
- Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency.Clinical pharmacokinetics · 2022Article
- Cryptogenic oozers and bruisers.Hematology. American Society of Hematology. Education Program · 2021Article
- Fibrinolysis in Platelet Thrombi.International journal of molecular sciences · 2021Review
- Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.International journal of molecular sciences · 2021Review
- Functional and Structural Characterization of Nucleic Acid Ligands That Bind to Activated Coagulation Factor XIII.Journal of clinical medicine · 2021Article
- Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.International journal of molecular sciences · 2021Review
- Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Factor XIII, a heterotetrameric proenzyme, is converted to an activated transglutaminase by thrombin and calcium in the final phases of coagulation. Factor XIII catalyzes the formation of crosslinks between fibrin monomers and between α2-antiplasmin and fibrin. These crosslinks mechanically stabilize fibrin against shear stress, enable red cell retention within the clot, and protect the clot from premature degradation. Congenital factor XIII deficiency is caused by autosomal recessive mutations, presenting early in life with a severe bleeding diathesis. Acquired deficiency may be caused by autoimmunity. Currently available assays for laboratory diagnosis of factor XIII deficiency include clot solubility assays, quantitative factor XIII activity assays, factor XIII antigen assays, and genetic testing. The International Society on Thrombosis and Haemostasis Scientific and Standardization Committee has recommended an algorithm for the laboratory diagnosis and differentiation of the different forms of factor XIII deficiency. However, implementation of this algorithm has been limited by technical and budgetary challenges associated with the currently available factor XIII-specific assays. The purpose of this review is to discuss the advantages and limitations of the currently available assays employed for the laboratory diagnosis of factor XIII deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.